Asieris Pharmaceuticals

Asieris Pharmaceuticals (亚虹医药, 688176.SH) is a Shanghai-listed global innovative drug company focused on genitourinary-system tumors and women's health, and a Qiming Venture Partners portfolio company. Its pipeline spans both oncology and adjacent areas: per Qiming's portfolio updates, its self-developed FGFR2/3 dual-target small-molecule inhibitor APL-2401 won NMPA approval in late 2025 for a Phase I trial in advanced solid tumors — cleared in just 22 working days under the regulator's new "30-day channel," among the first projects approved under that policy — while its oral drug APL-1401 posted positive preliminary Phase 1b results in moderate-to-severe ulcerative colitis in mid-2025. On the commercial side, it signed a strategic partnership with Xilingyuan Pharmaceutical in early 2025 around gynecological oncology products, aiming to accelerate eribulin commercialization alongside its own breast and gynecological cancer布局. It also maintains an R&D collaboration with ReviR Therapeutics, applying ReviR's AI drug-discovery platform and RNA-targeting technology to genitourinary tumors, per a 5Y Capital monthly.